Cargando…

Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS

Background: Group B Streptococcus (GBS) is a major contributor to the high burden of neonatal and young infant infectious disease in resource- limited settings. As disease protection during the first six months of life is provided via placental transfer of maternal antibodies, a maternal GBS vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyohere, Mary, Davies, Hannah Georgia, Musoke, Philippa, Nakimuli, Annettee, Tusubira, Valerie, Tasimwa, Hannington Baluku, Nsimire, Juliet Sendagala, Heath, Paul, Cose, Stephen, Baker, Carol, Le Doare, Kirsty, Sekikubo, Musa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706450/
https://www.ncbi.nlm.nih.gov/pubmed/33299966
http://dx.doi.org/10.12688/gatesopenres.13183.2
_version_ 1783617155651076096
author Kyohere, Mary
Davies, Hannah Georgia
Musoke, Philippa
Nakimuli, Annettee
Tusubira, Valerie
Tasimwa, Hannington Baluku
Nsimire, Juliet Sendagala
Heath, Paul
Cose, Stephen
Baker, Carol
Le Doare, Kirsty
Sekikubo, Musa
author_facet Kyohere, Mary
Davies, Hannah Georgia
Musoke, Philippa
Nakimuli, Annettee
Tusubira, Valerie
Tasimwa, Hannington Baluku
Nsimire, Juliet Sendagala
Heath, Paul
Cose, Stephen
Baker, Carol
Le Doare, Kirsty
Sekikubo, Musa
author_sort Kyohere, Mary
collection PubMed
description Background: Group B Streptococcus (GBS) is a major contributor to the high burden of neonatal and young infant infectious disease in resource- limited settings. As disease protection during the first six months of life is provided via placental transfer of maternal antibodies, a maternal GBS vaccine may provide an effective strategy to reduce infectious death and disability. An efficacy study may be difficult because of the large sample size required and alternative approaches such as serocorrelates of protection based on natural antibody concentration are being considered. Such studies would need to be undertaken in high burden settings such as Uganda. We therefore aim to evaluate the feasibility and acceptability of a GBS sero-epidemiology study in Kampala, Uganda. Methods: This is a prospective cohort and nested case-control study, conducted across two-centres with two entry points. A) consecutive women and their infants at birth, with collection of maternal swab, cord and maternal blood, and follow up by telephone until the infant is 3 months old; B) any infant under 3 months of age, presenting with signs of sepsis to any of the paediatric units, with collection of blood culture, cerebrospinal fluid and nasopharyngeal swabs. Any infants identified as having GBS disease (defined as GBS isolated from a normally sterile site) will be recruited and followed up for two years to assess their neurodevelopment. A nested qualitative study will investigate stakeholder (pregnant women and their families, healthcare workers and community leaders) opinions of sampling for such a study and understanding and potential uptake of vaccines in pregnancy. Discussion: The primary aim is to determine anti-GBS antibody concentration in infants with GBS disease compared to healthy controls. Secondary outcomes include stillbirth and all-cause infection and acceptance of sample methods and vaccination. The findings will inform scalability and sustainability of the programme in Uganda.
format Online
Article
Text
id pubmed-7706450
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-77064502020-12-08 Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS Kyohere, Mary Davies, Hannah Georgia Musoke, Philippa Nakimuli, Annettee Tusubira, Valerie Tasimwa, Hannington Baluku Nsimire, Juliet Sendagala Heath, Paul Cose, Stephen Baker, Carol Le Doare, Kirsty Sekikubo, Musa Gates Open Res Study Protocol Background: Group B Streptococcus (GBS) is a major contributor to the high burden of neonatal and young infant infectious disease in resource- limited settings. As disease protection during the first six months of life is provided via placental transfer of maternal antibodies, a maternal GBS vaccine may provide an effective strategy to reduce infectious death and disability. An efficacy study may be difficult because of the large sample size required and alternative approaches such as serocorrelates of protection based on natural antibody concentration are being considered. Such studies would need to be undertaken in high burden settings such as Uganda. We therefore aim to evaluate the feasibility and acceptability of a GBS sero-epidemiology study in Kampala, Uganda. Methods: This is a prospective cohort and nested case-control study, conducted across two-centres with two entry points. A) consecutive women and their infants at birth, with collection of maternal swab, cord and maternal blood, and follow up by telephone until the infant is 3 months old; B) any infant under 3 months of age, presenting with signs of sepsis to any of the paediatric units, with collection of blood culture, cerebrospinal fluid and nasopharyngeal swabs. Any infants identified as having GBS disease (defined as GBS isolated from a normally sterile site) will be recruited and followed up for two years to assess their neurodevelopment. A nested qualitative study will investigate stakeholder (pregnant women and their families, healthcare workers and community leaders) opinions of sampling for such a study and understanding and potential uptake of vaccines in pregnancy. Discussion: The primary aim is to determine anti-GBS antibody concentration in infants with GBS disease compared to healthy controls. Secondary outcomes include stillbirth and all-cause infection and acceptance of sample methods and vaccination. The findings will inform scalability and sustainability of the programme in Uganda. F1000 Research Limited 2020-11-13 /pmc/articles/PMC7706450/ /pubmed/33299966 http://dx.doi.org/10.12688/gatesopenres.13183.2 Text en Copyright: © 2020 Kyohere M et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Kyohere, Mary
Davies, Hannah Georgia
Musoke, Philippa
Nakimuli, Annettee
Tusubira, Valerie
Tasimwa, Hannington Baluku
Nsimire, Juliet Sendagala
Heath, Paul
Cose, Stephen
Baker, Carol
Le Doare, Kirsty
Sekikubo, Musa
Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS
title Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS
title_full Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS
title_fullStr Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS
title_full_unstemmed Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS
title_short Seroepidemiology of maternally-derived antibody against Group B Streptococcus (GBS) in Mulago/Kawempe Hospitals Uganda - PROGRESS GBS
title_sort seroepidemiology of maternally-derived antibody against group b streptococcus (gbs) in mulago/kawempe hospitals uganda - progress gbs
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706450/
https://www.ncbi.nlm.nih.gov/pubmed/33299966
http://dx.doi.org/10.12688/gatesopenres.13183.2
work_keys_str_mv AT kyoheremary seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT davieshannahgeorgia seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT musokephilippa seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT nakimuliannettee seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT tusubiravalerie seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT tasimwahanningtonbaluku seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT nsimirejulietsendagala seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT heathpaul seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT cosestephen seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT bakercarol seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT ledoarekirsty seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs
AT sekikubomusa seroepidemiologyofmaternallyderivedantibodyagainstgroupbstreptococcusgbsinmulagokawempehospitalsugandaprogressgbs